Tenet Healthcare Corp (THC) Q3 2026 Earnings Call Highlights: Strong EPS Growth
Tenet Healthcare Corp (THC) reported Q3 2026 adjusted diluted EPS of $6.64, up 80%, driven by strong core business growth. USPI adjusted EBITDA rose 9% to $537 million, while hospital segment admissions grew 3.2%. Full-year 2026 adjusted EBITDA guidance was raised by $195 million. Challenges include exchange admissions decline and Conifer transition impacts. Management remains optimistic about 2027 earnings growth.
How this was made
The 30-second read
Why it matters
Traders can update near-term positioning based on the raised 2026 adjusted EBITDA guidance and strong Q3 EPS/EBITDA, while also reassessing 2027 earnings quality given the non-recurring Conifer transition items and potential Medicaid/exchange headwinds.
Market read
Company-specific earnings and guidance updates with explicit 2027 normalization and volume/policy risks make this actionable for healthcare equity positioning.
What to watch
Exchange admissions/revenues declined 18% and same-facility case volumes fell 1.5%, suggesting underlying demand softness that could reassert itself even if cost actions and high-acuity mix support margins.
Background
The article summarizes Tenet Healthcare’s Q3 2026 earnings call, highlighting adjusted EPS/EBITDA performance, full-year guidance changes, and management commentary on 2027 normalization and policy-driven volume risks.
Ticker impact
Tenet reported Q3 2026 adjusted diluted EPS up 80% to $6.64 and raised full-year 2026 adjusted EBITDA guidance to $5.05-$5.2B.
Likely upward bias as the market prices in higher 2026 EBITDA, while investors may temper 2027 expectations due to the $450M non-recurring Conifer contribution and exchange/Medicaid headwinds.
The article contains multiple company-specific, decision-relevant datapoints: Q3 EPS/EBITDA performance, raised full-year guidance, and explicit 2027 normalization and policy/volume risks.
Market effects
Hospital and ASC operators may see read-through on demand durability and the sustainability of margin gains amid exchange and Medicaid policy uncertainty.
US healthcare services sentiment may improve near-term on raised EBITDA guidance, but 2027 volume concerns could weigh on the group.
Limited direct global impact; primarily affects US healthcare equities and healthcare credit sentiment.
Counterpoint
The raised 2026 EBITDA guidance may be partly offset by the explicit $450M Conifer transition contribution that will not recur in 2027, so the market may refocus on normalized earnings power rather than headline growth.
Key entities
- companyTenet Healthcare Corp
US hospital and ASC operator reporting Q3 2026 results and raising full-year 2026 adjusted EBITDA guidance, with 2027 normalization and policy risks discussed on the call.
- executiveSun Park
Tenet CFO, cited on guidance, revenue timing shift, and cost/efficiency commentary.
- executiveSam Sutaria
Tenet CEO, cited on surgical environment, USPI growth engine, and 2027 earnings outlook.
